The Administrative Core of the Yale SPORE in Skin Cancer (YSPORE) consists of the PI, Ruth Halaban, and the two Co-PIs Mario Sznol and Robert Tigelaar. The main responsibilities of the three directors are to lead the program, set basic and translational research priorities, identify new translational research opportunities from cutting-edge scientific progress, engage new investigators in skin cancer research, address critical issues, monitor progress, oversee the performance of the Cores and Projects, promote communication and collaboration among scientists in Yale and other SPOREs, introduce changes in YSPORE's projects and direction of translational research as required, and participate in recruiting new investigators in the field of skin cancer to the Yale Cancer Center/Yale School of Medicine. Major decisions are reached after discussions with the Executive Committee, composed of several leaders of projects and cores, and the Internal and External Boards of Advisors. The directors handle the day-to-day administration of the YSPORE. They work as a team to ensure efficient information transfer between Investigators, cost-effective operation of the projects, and sharing of resources to avoid duplication, proper deployment of core facility resources, comprehensive data management and archiving, and maintenance of the infrastructure required for all YSPORE-related studies. The directors also seek new funding from donors or other venues that facilitate the expansion of the YSPORE translational research. They manage and distribute new funding, foster novel pilot projects and clinical trials, ensure balanced representation of ethnic-racial/gender populations, and provide oversight and management of the financial and administrative aspects of the YSPORE. The Administrative Core serves as the liaison with the leadership of the Yale Comprehensive Cancer Center, coordinates YCCC activities with Skin Cancer SPORE activities, organizes meetings, schedules invited speakers, and encourages the participation of YSPORE scientists in national SPORE workshops.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121974-08
Application #
8719046
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06510
Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075
Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720
Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152
Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533
Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45
Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279

Showing the most recent 10 out of 172 publications